These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 28971503)

  • 1. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
    Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
    Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
    Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
    Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
    Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
    Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
    Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation.
    Kapke JT; Epperla N; Shah N; Richardson K; Carrum G; Hari PN; Pingali SR; Hamadani M; Karmali R; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):408-414. PubMed ID: 28756899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
    Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
    Stamatoullas A; Brice P; Gueye MS; Mareschal S; Chevallier P; Bouabdallah R; Nguyenquoc S; Francois S; Turlure P; Ceballos P; Monjanel H; Bourhis JH; Guillerm G; Mohty M; Biron P; Cornillon J; Belhadj K; Bonmati C; Dilhuydy MS; Huynh A; Bernard M; Chrétien ML; Peffault de Latour R; Tilly H
    Bone Marrow Transplant; 2016 Jul; 51(7):928-32. PubMed ID: 27042842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
    Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
    Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.
    Avivi I; Boumendil A; Finel H; Nagler A; de Sousa AB; Santasusana JMR; Vandenberghe E; Afanasyev B; Bordessoule D; Moraleda JM; Garcia EC; Pohlreich D; Garcia GG; Thomson K; Or R; Beelen D; Zuffa E; Giebel S; Berthou C; Salles G; Melpignano A; Montoto S; Dreger P
    Bone Marrow Transplant; 2018 Aug; 53(8):1001-1009. PubMed ID: 29463854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
    Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
    Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
    Song Y; Yin Q; Wang J; Wang Z
    Cell Transplant; 2021; 30():9636897211057077. PubMed ID: 34743574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.